Abstract
Introduction: Nevoid basal cell carcinoma syndrome (NBCCS) is a hereditary disease characterized by aberrant hedgehog pathway activation and development of multiple BCCs. Sonidegib is a hedgehog inhibitor approved for treatment of advanced BCCs. This secondary analysis evaluated sonidegib treatment on lesion size through 12 weeks in patients with NBCCS.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
